A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

This is a multicenter, Phase 2 Simon 2-Stage study designed to assess the safety, tolerability, PK, and efficacy of oral zelavespib (PU-H71) administered daily in adults with accelerated phase (10% to 19% blasts in peripheral or bone marrow) myeloproliferative neoplasm, with or without ongoing concomitant treatment with ruxolitinib.

Inclusion Criteria:Able to provide signed informed consent and willing to comply with the requirements and restrictions listed in the informed consent form and in this protocolAged ≥ 18 yearsConfirmed diagnosis of accelerated phase (10% to 19% blasts in peripheral blood or bone marrow) MPN arising on the background of previous PMF, PV, or ETPatients taking ruxolitinib must have been taking it for at least 3 months, with a stable dose at least 1 month before Cycle 1 Day 1Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2Acceptable organ function at screening, defined by the following criteria:absolute neutrophil count (ANC) ≥ 500/µLplatelet count ≥ 50,000/µLalanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2 × the upper limit of normal (ULN )total serum bilirubin ≤ 1.5 × ULNcreatinine clearance > 25 mL/min/1.73 m2 based on the Cockcroft-Gault equationWomen of childbearing potential (defined as premenopausal or within 2 years of the onset of menopause, and not surgically sterile) must meet both the following criteria:negative urine or serum pregnancy test at screening and within 72 hours before the first dose of zelavespibagree to use one of the following acceptable method of highly effective contraception for the duration of the study and for 13 weeks after the final dose of study treatmentMen must agree to the following requirements:a. men who are sexually active with women of childbearing potential must agree to the following requirements for the duration of their participation in the study and for 13 weeks after the final dose of study treatment: i. if the method of contraception is abstinence from penile vaginal intercourse as a usual and preferred lifestyle (abstinent on a long-term and persistent basis), men must agree to remain abstinent ii. if having penile vaginal intercourse with a nonpregnant, non-breastfeeding woman of childbearing potential, men must use a male condom, and their female partner must use a highly effective contraceptive method with a failure rate < 1% per year iii. men with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration iv. men must refrain from donating spermExclusion Criteria:Known active liver disease, including viral hepatitis or cirrhosisKnown or suspected infection with human immunodeficiency virus (HIV) or other active infection requiring acute or chronic treatment with systemic antibiotics (conditions requiring topical antibiotics are not exclusionary)Positive for HIV 1 or 2, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies at screeningPrevious treatment with a hypomethylating agentCorrected QT interval using Fridericia's formula (QTcF) > 480 ms at screening or baseline ECG based on the median value of ECGsPersonal or family history of long QT syndrome or taking any medication within 1 week or 5 half-lives (whichever is longer) before Cycle 1 Day 1 that carries a risk of Torsades de PointesLeft ventricular ejection fraction ≤ 50% or below the institution's lower limit of normal (whichever is lower) by echocardiogram or multigated acquisition (MUGA) scanCoronary artery disease with an ischemic event within 6 months before screeningHistory of a second primary malignancy within 6 months before screening that requires treatment with systemic antineoplastic agents, except for the following, if appropriately treated and considered cured: Stage 1 endometrial cancer, surgically treated cervical or prostate carcinoma, and nonmelanoma skin cancer Note: Subjects who are receiving adjuvant or preventive therapy for indolent cancers may be eligible, and the investigator should discuss with the medical monitor.Any significant uncontrolled medical condition, as determined by the investigator, within 6 months before screeningPlanned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN, with the exception of ruxolitinibUse of systemic corticosteroids (ie, prednisone > 20 mg/day or equivalent within 2 weeks before Cycle 1 Day 1Planned or current use of strong cytochrome P450 (CYP)3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer, for a maximum of 4 weeks) before Cycle 1 Day 1Planned or current use of herbal preparations/medications within 7 days before Cycle 1 Day 1Previous exposure to zelavespib (PU-H71)Uncontrolled diabetes mellitus, in the opinion of the investigatorAny other condition or laboratory abnormality or receiving any other treatment that, in the opinion of the investigator, may increase the risk associated with study participation or that may interfere with interpretation of the study resultsActive ocular condition (eg, ocular inflammatory disease that, in the opinion of the investigator, may worsen during the course of the study, or a history or anticipation of major ocular surgery (eg, cataract extraction or other intraocular surgery) during the studyCurrently pregnant or breastfeeding, or planning to become pregnantHistory of gastrointestinal surgery or current gastrointestinal condition that could affect the absorption of oral medication